Tually show illness progression. RCTs of agents for second-line treatment immediately after
Tually show disease progression. RCTs of agents for second-line treatment just after sorafenib failure had been damaging till a phase III multicentre RCT of regorafenib, a multikinase inhibitor chemically associated…